Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Max M. Quinn, Xiaoen Wang, Cyril H. Benes, Ashley A. Merlino, Qingsong Liu, Yuyang Li, Peng Gao, Kwok-Kin Wong, Nathanael S. Gray, Feiyang Liu, Fei Li, Yan Liu
Publikováno v:
Cancer Research. 77:5068-5076
Cells lacking the tumor suppressor gene LKB1/STK11 alter their metabolism to match the demands of accelerated growth, leaving them highly vulnerable to stress. However, targeted therapy for LKB1-deficient cancers has yet to be reported. In both Kras/
Autor:
Yu Shyr, Li-Ching Huang, Charalambos C. Solomides, Yunguang Sun, Adam P. Dicker, Yong Antican Wang, Joshua D. Palmer, Bo Lu
Publikováno v:
Molecular Cancer Research. 15:896-904
Insulin-like growth factor binding protein 3 (IGFBP3) modulates cell growth through IGF-dependent and -independent mechanisms. Reports suggest that the serum levels of IGFBP3 are associated with various cancers and that IGFBP3 expression is significa
Autor:
Félix Bonilla, Cristina Peña, Belén Pérez-Sacristán, F. Granado-Lorencio, Gemma Domínguez, Beatriz Gil-Calderón, Jesús Espinosa Romero, Encarnación Donoso, Coral San Millán, Beatriz Soldevilla, Marta Compte, Paloma Martín
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background]: The acquired resistance to chemotherapy represents the major limitation in the treatment of cancer. New strategies to solve this failure and improve patients' outcomes are necessary. The cancer preventive effect of β-cryptoxanthin has
Autor:
Claire Oudin, Jean-Marc Riedinger, Sarab Lizard-Nacol, Frédérique Végran, Romain Boidot, Franck Bonnetain
Publikováno v:
Clinical Cancer Research. 12:5794-5800
Purpose: CASP-3 gene gives rise, by alternative splicing to a caspase-3s variant, to the antagonist apoptotic property of caspase-3. Deregulation of splicing in tumor cells favoring the expression of antiapoptotic variants has been reported to contri
Autor:
Sandy Livingston, Craig A. Beam, Marek Wloch, Nills Diaz, Richard Jove, Tammy Bowman, Ibrahim Eweis, Susan Minton, Carlos A. Muro-Cacho, Ed Seijo, Roy Garcia, Charles E. Cox, Alan B. Cantor, Daniel M. Sullivan, Ji-Hyun Lee, Tanya Gritsko
Publikováno v:
Clinical Cancer Research. 12:20-28
Purpose: Constitutive activation of signal transducer and activator of transcription 3 (Stat3) protein has been observed in a wide variety of tumors, including breast cancer, and contributes to oncogenesis at least in part by prevention of apoptosis.
Publikováno v:
Cancer Research. 64:1737-1743
PC cell-derived growth factor, also known as progranulin, is an Mr 88,000 growth factor (referred as PCDGF/GP88) overexpressed in human breast cancer. Antisense inhibition of PCDGF/GP88 expression in MDA-MB-468 cells inhibited tumor formation in nude
Publikováno v:
Cancer Research. 77:185-185
The incidence of pediatric and adult brain tumors has continued to rise and temozolomide (TMZ) has remained the sole choice for chemotherapy of these cancers. A number of factors including the inefficient drug entry through the BBB, intratumoral hete
Autor:
Hailing Yang, Guo-fu Hu
Publikováno v:
Cancer Research. 74:3934-3934
Glioblastoma (GBM) tumors secrete high level of angiogenic factors and feature vascular abnormality. Targeted therapy, such as Bevacizumab, which neutralizes VEGF and normalizes tumor vasculature, has been approved to treat recurrent GBM. However, it
Autor:
Jerry Pelletier, Denis Gaucher, Ryan D. Morin, Koren K. Mann, Randy D. Gascoyne, Nathalie A. Johnson, Joseph M. Connors, Marco A. Marra, Hawley Rigsby
Publikováno v:
Cancer Research. 74:959-959
Lymphomas are common (1/30 Canadians), but responses to chemotherapy depend on the tumour biology. We sequenced > 300 lymphomas at diagnosis and at relapse, identified FAS as a possible tumour suppressor gene and found that mutant FAS is associated w
Autor:
Steven Mog, Eugene H. Herman, Ashutosh Rao, Baikuntha P. Aryal, Yanira Gonzalez-Berrios, Karen P. Mason, William M. Bonner, Christophe E. Redon, Palak R. Parekh, Ulrich Baxa, Jennifer S. Dickey, Asako J. Nakamura, Elliot T. Rosen
Publikováno v:
Cancer Research. 73:1386-1386
Doxorubicin is a chemotherapeutic drug that causes oxidative stress-mediated cardiotoxicity. To prevent oxidative stress and help to mitigate the cardiotoxic effects of doxorubicin, the iron chelator dexrazoxane is clinically used. However, iron chel